Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications

Multiple Sclerosis Journal

Volumn 22, Issue 3, 2016, Pages 312-319

  Cobo Calvo, Álvaro ^a   Sepúlveda, María ^b   Bernard Valnet, Raphael ^c,d   Ruiz, Anne ^e   Brassat, David ^c,d   Martínez Yélamos, Sergio ^a   Saiz, Albert ^b   Marignier, Romain ^e,f  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e LYON NEUROSCIENCE RESEARCH CENTER   (France)

^f Groupement Hospitalier Est   (France)

Author keywords

Aquaporin 4 antibody; Longitudinally extensive transverse myelitis; Multiple sclerosis; Myelin oligodendrocyte glycoprotein; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RITUXIMAB;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; PLASMAPHERESIS; PLEOCYTOSIS; RETROSPECTIVE STUDY;

EID: 84962878107     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515591071     Document Type: Article

References (26)

1. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
2. Trebst C, Raab P, Voss EV, et al. Longitudinal extensive transverse myelitis-it's not all neuromyelitis optica. Nat Rev Neurol 2011; 7: 688-698.
3. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59: 566-569.
4. Hyun J-W, Kim S-H, Huh S-Y, et al. Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. Mult Scler. 2015 May; 21: 710-7.
5. Kitley J, Leite MI, Küker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 2013; 70: 1375-1381.
6. Chang K-H, Lyu R-K, Chen C-M, et al. Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies. Mult Scler 2013; 19: 299-307.
7. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013; 80: 2194-2200.
8. Von Büdingen HC, Tanuma N, Villoslada P, et al. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J Clin Immunol 2001; 21: 155-170.
9. Reindl M, Di Pauli F, Rostásy K, et al. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9: 455-461.
10. Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011; 138: 247-254.
11. Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015; 86: 265-72.
12. Rostásy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013; 19: 1052-1059.
13. Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012; 69: 752-756.
14. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol 2014; 71: 276-283.
15. Höftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015; 21: 866-74.
16. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474-481.
17. Confavreux C, Compston DA, Hommes OR, et al. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671-676.
18. Barnes G, Benjamin S, Bowen D, et al. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59: 499-505.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983;33: 1444-1452.
20. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
21. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38: 180-185.
22. Höftberger R, Sabater L, Marignier R, et al. An optimized immunohistochemistry technique improves NMO-IgG detection: Study comparison with cellbased assays. PLoS One 2013; 8: e79083.
23. Pröbstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011; 77: 580-588.
24. Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation 2014; 1: e40.
25. Saadoun S, Waters P, Owens GP, et al. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2014; 2: 35.
26. Ikeda K, Kiyota N, Kuroda H, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelinoligodendrocyte glycoprotein antibody. Mult Scler. 2015; 21: 656-9.